GSK eyeing dermatology, biotech buyouts
GlaxoSmithKline Pharmaceuticals is keen on acquiring brands and has identified some targets. It is also all set to introduce two drugs, one each for cardio-vascular and critical care through in-licensing tie-ups, within 2-3 weeks.
“We are open to acquire brands in segments such as dermatology, cardio vascular, biotech and antibiotic apart from the segments we are present,” said Hasit Joshipura, MD, GlaxoSmithKline Pharmaceuticals.
"Based on where we see an opportunity, where our strength lies we would decide and set our targets, he added without divulging further details. We are at the final stages of negotiations with a couple of foreign companies, and hope to sign the final agreement in 3 weeks time," Joshipura said.
Out of the two drugs one would be manufactured on India and the other would be imported.
The in-licensing strategy where GSK ties-up with another company to sell its drugs in India, is a concept unique to India and the company has eight such tie-ups.
Source:
